Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 5/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.41 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890714 | 0.84 | TGM2 (0.58) | TGM2HPGDKDM4EALDH1A1RECQL | |
| SCHEMBL29367186 | 0.84 | TGM2 (0.58) | TGM2HPGDKDM4EALDH1A1RECQL | |
| SCHEMBL2863439 | 0.83 | KDM4E (0.50) | TGM2PTPN1PTPN11HPGDKDM4E | |
| SCHEMBL31228347 | 0.82 | TGM2 (0.65) | TGM2PTPN1PTPN11KDM4EALDH1A1 | |
| SCHEMBL613090 | 0.82 | TGM2 (0.65) | TGM2PTPN1PTPN11KDM4EALDH1A1 | |
| SCHEMBL899121 | 0.82 | TGM2 (0.52) | TGM2PTPN1PTPN11HPGDKDM4E | |
| SCHEMBL946592 | 0.82 | KDM4E (0.66) | TGM2HPGDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7754798 | 0.79 | ALDH1A1 (0.58) | TGM2PTPN1PTPN11HPGDKDM4E | |
| SCHEMBL4736645 | 0.79 | HPGD (0.68) | HPGDKDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL29352351 | 0.79 | ALDH1A1 (0.58) | TGM2PTPN1PTPN11HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-01-13 | — | — | US | claimed |
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-01-13 | — | — | US | disclosed |
| WO-2004063195-A1 | PYRIDOPYRIMIDINE KINASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | MAP3K1, MAP3K19, MAP3K20 | TGM2 2131/4885PTPN1 418/4885PTPN11 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.